Biology of childhood osteogenic sarcoma and potential targets for therapeutic development: meeting summary.
Richard Görlick(The University of Texas MD Anderson Cancer Center), Barry Anderson(National Institutes of Health), Holcombe E. Grier(Harvard University), Andrew G. Huvos(Memorial Sloan Kettering Cancer Center), John H. Healey(Memorial Sloan Kettering Cancer Center), Paul S. Meltzer(National Cancer Institute), Cindy L. Schwartz(Brown University), Julia A. Bridge(Nebraska Medical Center), Thomas A. Gardner(Indiana University), Nai‐Kong V. Cheung(Memorial Sloan Kettering Cancer Center), Marc Ladanyi(Memorial Sloan Kettering Cancer Center), Malcolm A. Smith(National Cancer Institute), Irene L. Andrulis(University of Toronto), Jon M. Wigginton(Bristol-Myers Squibb (United States)), Deborah E. Schofield(University of Southern California), Mason Schoenfeldt(Alkermes (Ireland)), Maria Tsokos(Beth Israel Deaconess Medical Center), Janet M. Hock(Indiana University), David H. Ebb(Harvard University Press), Peter M. Anderson(Mayo Clinic in Arizona), Jeffrey S. Dome(Children's National), Lee J. Helman(American Osteopathic Association), Mark L. Bernstein(University of Louisville), Eugenie S. Kleinerman(The University of Texas MD Anderson Cancer Center), Peter J. Houghton(The University of Texas at San Antonio Health Science Center), Ching C. Lau(University of Hong Kong), Leonard H. Wexler(Memorial Sloan Kettering Cancer Center), Mark C. Gebhardt(Boston Children's Hospital), Jeffrey A. Toretsky(Georgetown University), G. Peter Beardsley(Yale University), Neyssa Marina(Coherus BioSciences (United States)), David Malkin(University of Toronto), Marc F. Hansen(University of Connecticut), Janet A. Houghton(Cleveland Clinic), Stephen J. Withrow(Colorado State University), Carola Arndt(Mayo Clinic), Chand Khanna(Drug Discovery Laboratory (Norway)), Mark W. Kieran(Children Cancer Hospital), Paul A. Meyers(Memorial Sloan Kettering Cancer Center)
PubMed
November 15, 2003
Cited by 198
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
|New England Journal of Medicine|2012|8k
Nivolumab plus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2013|4.2k
The landscape of somatic copy-number alteration across human cancers
|Nature|2010|4.1k
Chronic Health Conditions in Adult Survivors of Childhood Cancer
|New England Journal of Medicine|2006|3.6k